GSK to Present 43 Abstracts Across Respiratory Portfolio at ATS 2025, Including New Data on Mepolizumab and Depemokimab
GSK plc (LSE/NYSE: GSK) today announced that 43 abstracts, including four late-breaking submissions, from its inhaled and respiratory biologics portfolio will be presented at the 2025 American Thoracic Society (ATS) International Congress in San Francisco, taking place from 16–21 May. These data underscore GSK’s continued commitment to advancing the understanding and treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
New Insights from the MATINEE Phase III Trial
New sub-analyses from the MATINEE trial, recently published in The New England Journal of Medicine, build on existing evidence supporting mepolizumab in patients with COPD and type 2 inflammation. The analyses focus on reductions in COPD exacerbations, including those leading to emergency department visits and/or hospitalisations. Subgroups assessed include patients with cardiovascular comorbidities, differing levels of airflow obstruction, and those with chronic bronchitis, emphysema, or both. Additionally, a new analysis explores the association between severe exacerbation risk and healthcare resource utilisation.
Updated Findings from SWIFT-1 and SWIFT-2 Trials on Depemokimab
Data from the SWIFT-1 and SWIFT-2 Phase III trials, evaluating twice-yearly depemokimab for asthma with type 2 inflammation, include:
- A post hoc analysis of exacerbations and quality of life in patients with uncontrolled symptoms
- A pooled assessment demonstrating improvements in health status and exacerbation risk through sustained suppression of type 2 inflammation
- Subgroup findings on geographical variation in exacerbation rates, with specific insights from China, where access to respiratory biologics was limited during the trial
Late-Breaking Real-World Evidence on Biologic Adherence
In a late-breaking session, GSK will present the first real-world study of its kind assessing the relationship between adherence to biologic treatments and clinical outcomes such as asthma exacerbations and oral corticosteroid use.
Broader Efforts to Address Complex Respiratory Challenges
Other presentations include:
- Data on camlipixant for refractory chronic cough (RCC), featuring a model-based dose–response meta-analysis on reducing P2X3 class-related taste disturbances
- A real-world European cohort study evaluating the potential for clinical remission in severe asthma patients treated with mepolizumab
- New findings on the carbon footprint of salbutamol (albuterol) delivered via current and next-generation metered dose inhalers (MDIs) and dry powder inhalers (DPIs), supporting GSK’s environmental sustainability initiatives
| Abstract Name | Presenter | Presentation Details |
|---|---|---|
| Mepolizumab | ||
| Mepolizumab Reduces the Risk of Severe Exacerbations and Healthcare Resource Utilization in Chronic Obstructive Pulmonary Disease: Results from the MATINEE Phase III Randomized Controlled Trial | Gerard J. Criner | Oral PresentationAbstract #10581Session C14 |
| Mepolizumab is Efficacious in Patients with Chronic Obstructive Pulmonary Disease Regardless of Airflow Obstruction Level: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial | MeiLan K. Han | Poster DiscussionAbstract #8812Poster Board #1017Session B101 |
| Mepolizumab is Efficacious in Patients with Chronic Obstructive Pulmonary Disease Regardless of Investigator-Reported Chronic Bronchitis and/or Emphysema: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial | Ian D. Pavord | Poster DiscussionAbstract #8746Poster Board #1012Session B101 |
| Mepolizumab is Efficacious in Patients With Chronic Obstructive Pulmonary Disease Regardless of Disease Duration: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial | Nicolas Roche | Late-breakerPoster Board #P669Session C33 |
| St. George’s Respiratory Questionnaire Scores in Patients With Chronic Obstructive Pulmonary Disease Receiving Mepolizumab: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial | Paul W. Jones | Late-breakerPoster Board #P671Session C33 |
| Clinical Remission Is an Achievable Goal for Patients with Severe Asthma Receiving Mepolizumab in Europe: A Chart Review | Stephen G. Noorduyn | Thematic PosterAbstract #8721Poster Board#P1461Session A39 |
| Mepolizumab Efficacy is Durable up to 104 Weeks in Patients with Chronic Obstructive Pulmonary Disease: Results from the MATINEE Phase III Randomized Controlled Trial | Mona Bafadhel | Thematic PosterAbstract #10722Poster Board#P1380Session A32 |
| Mepolizumab is Efficacious Regardless of Severity of Prior Chronic Obstructive Pulmonary Disease Exacerbations: Post Hoc Analysis of the MATINEE Phase III Randomized Controlled Trial | Alberto Papi | Thematic PosterAbstract #10648Poster Board#P1366Session A32 |
| Mepolizumab is Effective in Reducing Exacerbations in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Comorbidities: Results from the MATINEE Phase III Randomized Controlled Trial | Claus F. Vogelmeier | Thematic PosterAbstract #10604Poster Board#P1367Session A32 |
| Depemokimab | ||
| Twice-Yearly Depemokimab Reduces Exacerbations and Improves Quality of Life in Patients with Uncontrolled Asthma Symptoms at Baseline: Subgroup Analyses of the Phase III SWIFT-1/2 Studies | Ian D. Pavord | Oral PresentationAbstract #10692Session C14 |
| Sustained Efficacy of Depemokimab Over Time in Type 2 Asthma Characterized by Blood Eosinophils: Pooled Data from the Phase III SWIFT‑1/2 Studies | Michael E. Wechsler | Poster DiscussionAbstract #6969Poster Board #1007Session B101 |
| Real-World Persistence to Biologic Therapies and Its Impact on Outcomes in Patients with Asthma | Justin Kwiatek | Late-breakerPoster Board #724Session C101 |
| Regional Variation in Response to Depemokimab Versus Placebo in Patients with Asthma with Type 2 Inflammation: Subgroup Analyses of the Phase III SWIFT-1/2 Studies | David J. Jackson | Thematic PosterAbstract #12036Poster Board#P1382Session A32 |
| Exploring Global Geographic Variation in Exacerbation Rates in Randomized Controlled Trials of Biologics in Patients with Severe Asthma: A Systematic Literature Review | David J. Jackson | Thematic PosterAbstract #6796Poster Board#P1422Session A34 |
| Twice-Yearly Depemokimab Demonstrates Efficacy in Patients with Asthma in China and Japan: Subpopulation Analyses of the SWIFT-1/2 Studies | Toshiyuki Koya | Thematic PosterAbstract #11189Poster Board#P1429Session A34 |
| Fluticasone Furoate/Umeclidinium/Vilanterol | ||
| Effect of Chronic Mucus Hypersecretion on Patients with COPD Achieving and Maintaining Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Versus Budesonide/Formoterol: A FULFIL Post Hoc Analysis | Feng-yan Wang | Oral Presentation Abstract #10693 Session D14 |
| Exacerbation Reduction in Patients with Asthma Following Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in the United States | Stephen G. Noorduyn | Oral Presentation Abstract #9347 Session C16 |
| Assessment of Disease Stability in Patients with COPD Receiving Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI: Post Hoc Analysis of the IMPACT Trial | MeiLan K. Han | Oral PresentationAbstract #10784Session A15 |
| Impact of Fluticasone Furoate/Umeclidinium/Vilanterol Inhaled Therapy on a Clinical Remission Endpoint in Asthma for Patients with Type 2 Inflammation: CAPTAIN Post Hoc Analysis | Ian Pavord | Poster DiscussionAbstract #8928Poster Board #1010Session B101 |
| Impact of Simultaneous Step-Up to High-Dose Fluticasone Furoate and Addition of Umeclidinium on a Clinical Remission Endpoint in Asthma: CAPTAIN Post Hoc Analysis | Ian Pavord | Poster DiscussionAbstract #9064Poster Board #1011Session B101 |
| Comparison of Individual and Composite Measures to Assess Disease Stability Over Time in Patients with COPD Treated with Fluticasone Furoate/Umeclidinium/Vilanterol: A Post Hoc Analysis | MeiLan K. Han | Poster DiscussionAbstract #10779Poster Board #615Session B25 |
| Disease Stability, Management and Treatment Goals in Chronic Obstructive Pulmonary Disease Among Newly Diagnosed vs Long-Term Diagnosed Patients: A Patient Survey | David Halpin | Thematic PosterAbstract #10768Poster Board #P262Session B42 |
| Salbutamol (albuterol) | ||
| Decarbonizing Respiratory Care: The Impact of a Low-Carbon Salbutamol Metered‑Dose Inhaler | Maximilian Plank | Late-breakerPoster Board #P657Session C33 |
| Camlipixant | ||
| Investigating Camlipixant P2X3 Selectivity and Taste Disturbance: A Model-Based Dose–Response Meta-Analysis | Daren Austin | Thematic PosterAbstract #7825Poster Board #P109Session A54 |
| Effect of Camlipixant on Cardiac Repolarization in Healthy Participants: A Thorough QT/QTc Study | Elizabeth A. Duncan | Thematic PosterAbstract #8877Poster Board #P108Session A54 |
| A Scoping Literature Review of Digital Endpoints for Chronic Cough Over the Past Five Years: Closing the Gap Between Clinical Trials and Real-World Clinical Practice | Elizabeth P. Skinner | Thematic PosterAbstract #7776Poster Board #P256Session B42 |
About mepolizumab
Mepolizumab is a monoclonal antibody that targets and binds to IL-5, a key messenger protein (cytokine) in type 2 inflammation. Mepolizumab has been developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation. It is currently approved for use in the US and Europe across four IL-5 mediated conditions. Mepolizumab is not approved for the treatment of COPD in any country. Regulatory submissions are under review in several countries, including the US, China and the EU. The US FDA has provided a PDUFA date of May 7, 2025.
For product and important safety information please consult the country relevant summary of product characteristics.
About depemokimab
Depemokimab, a monoclonal antibody that targets IL-5, is the first ultra-long-acting biologic to be evaluated in phase III trials of patients with asthma with type 2 inflammation (SWIFT trials) or chronic rhinosinusitis with nasal polyps (CRSwNP) (the ANCHOR trials). Depemokimab’s extended half-life, high-binding affinity and potency, supported six-month (26 week) dosing regimens in these trials, and demonstrated early and sustained inhibition of markers of type 2 inflammation and IL-5 activity. The phase III programme includes evaluation of depemokimab in other IL-5 mediated diseases including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). The first phase III trials in severe asthma, SWIFT-1 and SWIFT-2, have been reported and published in the The New England Journal of Medicine and the phase III trials in CRSwNP, ANCHOR-1 and ANCHOR -2 have been published in The Lancet. Depemokimab is an investigational product and is not approved for use in any country. Regulatory submissions are under review, including in the US, China, Japan and the EU.
About GSK in respiratory
GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, GSK is focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression.
